MAP2K7 and neoplasm: The activation of MEK-ERK signaling was shown to promote the progression of malignant tumors, and HSV-1 increased the transport of the MEK1/2 kinase inhibitor, trametinib, across the BBB, leading to a reduction in the total number of TAMs at the tumor site.